Bio-Rad Laboratories reported second-quarter 2026 net sales of $651.0 million, essentially flat year-over-year, with Clinical Diagnostics growth offset by softness in Life Science. GAAP diluted earnings per share reached $13.85, significantly higher than the prior year's $11.67, driven primarily by a $458.0 million gain from changes in the fair market value of its investment in Sartorius AG. The company generated $99 million in operating cash flow and repurchased approximately $32 million of shares during the quarter. Concurrently, Bio-Rad initiated a global restructuring plan on July 31, 2026, to improve operating performance, estimating pre-tax charges of $80 to $90 million for workforce reductions and facility consolidations expected to be completed by the end of fiscal year 2027. Management reaffirmed its full-year non-GAAP revenue outlook of a decline of approximately 3.0 percent to growth of approximately 0.5 percent, with an estimated operating margin of 10.0 to 12.0 percent. Bio-Rad Laboratories operates in the life science research and clinical diagnostics industry, developing and manufacturing products for academic, hospital, and biopharmaceutical customers.